角膜手術全球市場-2022-2029
市場調查報告書
商品編碼
1140720

角膜手術全球市場-2022-2029

Global Corneal Surgery Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年角膜手術市場價值為 4.155 億美元。預計在預測期內(2022-2029 年)將以 6.20% 的複合年增長率增長。

角膜手術是一種移植手術,用捐贈者的角膜組織替換部分角膜。它涉及用器官捐獻者的健康組織替換患病或受損的角膜組織。角膜手術可以幫助恢復視力、減輕疼痛並改善受損或患病角膜的外觀。有幾個因素會損害角膜,包括真菌性角膜炎、倒睫、Fuchs 角膜炎、圓錐角膜等感染、眼外傷和角膜燒傷。

角膜手術可有效緩解與角膜疾病相關的體徵和症狀。角膜手術可以治療多種疾病,包括圓錐角膜、Fuchs角膜變性、角膜變薄、角膜瘢痕、角膜混濁、角膜腫脹和角膜潰瘍。

市場動態

由於視障人士的增加促進市場增長

隨著越來越多的人患有視力障礙,對角膜手術的需求也在增加。根據世界衛生組織 (WHO) 的數據,全世界約有 2.17 億人患有中度至重度視力障礙。此外,約有 3700 萬人失明。在全球範圍內,50 歲以上的人中有 82% 是盲人。根據 Surgical Eye Expeditions International 的數據,角膜是世界上導致失明的主要原因。全球約有 5.1% 的人口,即 1200 萬人因角膜問題而失明。角膜是視力喪失的主要原因,僅次於白內障、青光眼和年齡相關性黃斑變性。每年,全世界有超過 350,000 名兒童在出生時患有或在幼年時患上導致角膜失明的感染。

對角膜手術設備開發的資金和投資不斷增加,預計將在預測期內推動市場增長。

一些組織、協會和基金會正在加大對角膜手術設備開發的投資和資助。例如,2020 年 8 月,澳大利亞眼科研究中心和墨爾本大學的角膜研究人員宣布了一種名為 Corel 的手術設備,這是一種超薄水凝膠薄膜,可以插入供體角膜組織以恢復患者眼睛的視力。獲得維多利亞醫學研究加速基金 (VMRAF) 的 500,000 美元贈款,用於加速這筆資金將用於 18 個月的臨床前工作,以與大學和美國眼庫 EverSight 合作改進和測試 CorGel。

與角膜手術相關的不良事件阻礙市場增長

與角膜手術相關的一些不良事件正在阻礙市場增長。不良事件包括感染、出血、疼痛、發紅、對光敏感和眼壓升高。角膜手術會增加患眼部感染、晶狀體混濁、供體角膜排斥和角膜腫脹的風險。在十分之一的角膜移植中,身體的免疫系統會攻擊捐贈的組織。角膜排斥反應的發生率為 20%。接受角膜移植的患者也可能發生移植失敗。

COVID-19 影響分析

全球角膜手術市場受到 COVID-19 流行病的影響。這是因為隨著 COVID-19 患者人數的增加,接受角膜手術的患者人數正在減少。 COVID-19 可能對角膜手術的實施構成重大威脅。 COVID-19 大流行源於自願捐贈者數量與角膜手術之間的供需失衡。由於一些眼科醫生已經停止了所有非緊急和急救治療,因此接受角膜手術的人越來越少。此外,由於 COVID-19 大流行,每個國家的眼科醫院和眼庫都被禁止將死者的眼球帶回家。根據卡納塔克邦眼科學會的數據,由於缺乏供體眼球或 Covid 陰性檢測報告,角膜移植的數量下降了 90% 以上。許多患者無法進行角膜手術,因為他們沒有足夠的角膜進行角膜手術。根據 Parekh、Mohit 等人在 2020 年發表在《歐洲眼科學雜誌》上的數據,全球約有 270 萬患者正在等待角膜移植。威尼托眼庫見證了來自國內外 250 名外科醫生網絡的供體角膜減少了 95%。

流行病學

眼科角膜病是全球失明的主要原因。角膜眼病影響全球超過 1000 萬人。幾種疾病是全球角膜失明的主要原因,包括角膜混濁、沙眼、角膜瘢痕、角膜營養不良和角膜新生血管。根據世界衛生組織 (WHO) 的數據,大約有 1.46 億人患有沙眼。大約有 1000 萬人患有倒睫,需要通過手術來預防角膜失明。大約 490 萬人因沙眼導致的角膜瘢痕而失明。

根據全球視力數據庫,角膜混濁影響全球約 3*21% 的人口。角膜混濁佔東亞人口的4*26%,中亞人口的3.58%,南亞人口的2.43%,中歐人口的3.63%,東歐人口的3.43% ,和西歐3.43%的人口。據說影響2.43%。在美國,角膜營養不良的總體患病率為每 100,000 人中有 897 人。大約 60% 的角膜營養不良是內皮的。

市場細分

在角膜手術市場中,深前板層角膜移植術細分市場有望佔據很大份額

按移植類型,角膜手術市場分為深前板層角膜移植術、穿透性角膜移植術和合成角膜。深前板層角膜移植術是角膜手術治療市場的最大部分,因為越來越多地採用深前板層角膜移植術來治療圓錐角膜、角膜外翻、角膜基質營養不良和角膜瘢痕形成。預計將佔據份額。深前板層角膜移植術是一種將角膜基質去除至後彈力膜的外科手術。選擇性移植角膜基質的部分厚度角膜移植,留下原始的後彈力膜和內皮。它是對角膜前表面所有病變的有效治療,包括上皮、鮑曼層和基質。前段深部角膜移植術的使用表明,這種手術程序可以保留患者之間的宿主內皮,從而降低排斥率。接受深前板層角膜移植術的患者也經歷了更短的癒合時間、更少的術後並發症和更少的局部類固醇。

根據手術類型,預計穿透性角膜移植術在預測期內將顯著增長

市場按手術類型分為術前檢查、滲透性角膜移植術和板層角膜移植術。滲透性角膜移植術佔據了很大的市場份額,因為它是全世界最常進行的手術。根據辛辛那提眼科研究所 (CEI) 的數據,美國每年進行大約 45,000 例滲透性角膜移植手術。穿透性角膜移植術包括通過手術切除中央三分之二的受損角膜並插入匹配的清晰、健康的供體組織。用於角膜水腫、角膜潰瘍、角膜營養不良、Fuch氏營養不良、圓錐角膜等病症的治療和管理。研究表明,角膜移植可使患者存活 10 年或更長時間。

區域分析

北美在全球角膜手術市場中佔有最大的市場份額。

北美地區主導著全球角膜手術市場,並將在 2021 年佔據最大的市場份額。隨著盲人數量的增加,越來越多的人接受角膜手術,預計美國將在該地區佔據最大份額。根據美國疾病控制與預防中心 (CDC) 的數據,美國有 100 萬人失明,約 1200 萬人有視力障礙。根據美國眼科學會的數據,2013 年美國進行了大約 48,229 例角膜移植手術。自 1961 年以來,美國已有超過 100 萬名年齡在 9 天至 100 歲及以上的男性、女性和兒童通過角膜手術恢復了視力。

開發角膜手術設備的市場參與者數量正在增加。幾家公司已投資並籌集資金用於角膜手術設備的開發。先進的角膜手術方法的使用正在增加。有幾個組織、協會和基金會可以提高對角膜手術的認識。例如,美國角膜研究基金會 (CRFA) 是一家致力於角膜疾病、角膜移植和人工晶狀體手術的非營利性臨床研究和教育組織。此外,幾家公司正在推出外科視覺中心。例如,2019 年 7 月,強生公司在佛羅裡達州傑克遜維爾的強生研究所啟動了外科視覺體驗中心。該中心是 Johnson & Johnson Vision 首屈一指的體育訓練空間和實驗室,可用於各種體驗式教育計劃,為執業眼科醫生、眼科住院醫師和驗光師提供動手、深入的培訓。它將發揮作用。更好的醫療設施和基礎設施的可用性預計將刺激市場增長。

預計亞太地區在預測期內將以最快的複合年增長率增長

亞太地區是全球角膜估計是手術市場增長最快的地區。根據全球眼庫協會聯盟 (GAEBA) 的數據,亞洲約有 280 萬人受到角膜失明的影響。由於角膜疾病,大約 680 萬人的至少一隻眼睛的視力喪失為 6/60 或更少。其中,100 萬人患有雙側疾病。根據國家防治失明計劃(NPCB),2013 年印度有 120,000 人患有角膜失明。每年有 25,000 至 30,000 例新的角膜失明病例。此外,印度於 1976 年啟動了國家失明和視力障礙控制計劃,中央政府提供 100% 的資金,到 2020 年將失明率降至 0.3%。在 2016-17 年度,該計劃收集了用於角膜移植的捐贈眼睛,在 50,000 隻的目標中實現了 65,135 只。

由於眼科診所、醫院和其他進行角膜手術的醫療機構的增加,預計印度、中國、日本和澳大利亞等國家的市場將出現大幅增長。人們對捐眼重要性的認識日益提高,預計也將對市場產生積極影響。幾家公司專注於開發技術先進的角膜手術器械。政府正在加緊努力在診所和醫院提供低成本的眼科手術。眼保健設施、眼庫框架和角膜交易協議的改進預計將增加對角膜手術的需求。

競合情勢。

角膜手術市場是一個分散的市場,市場參與者眾多。 Nidek Co. Ltd.、Johnson & Johnson、Essilor International S.A.、Topcon Corporation、Ziemer Ophthalmic Systems AG、Carl Zeiss Meditec、Bausch &Lomb、Abbott Medical、Alcon Laboratories、Meditec AG、Medical Optics Inc 和 Cooper Vision 擁有較大的市場份額主要參與者。主要參與者採用了多種增長戰略,例如產品發布、產品批准、合併、許可、收購和合作夥伴關係,為全球角膜手術市場的增長做出了貢獻。例如:

合併與合作。

2019 年 10 月,TECLens 與 SERVimed Industrial Spa 合作開發和 FDA 批准治療圓錐角膜的新組合產品。正在開發的新產品結合了 TECLens 的 CXLens“眼上”交聯繫統,用於角膜重塑和 SERVImed 的跨上皮 RIBOCROSS 核黃素配方。

2022 年 7 月 18 日,Carl Zeiss Meditech 與 Plessis Bio 合作,開始開發和商業化用於眼科的加工角膜組織。根據該協議,Carl Zeiss Meditech 將投資 Precise Bio 開發角膜移植產品。

產品發布和批准

2021 年 5 月 24 日,Haag-Streit UK 在英國推出了眼科分析儀“Eyestar 900”。掃頻技術可以精確測量整個眼球,並對角膜的前後表面以及包括晶狀體的前房進行地形評估。除了對所有這些結構進行成像外,它還包括從角膜到視網膜的整個眼睛的生物特徵。

2019 年 7 月 31 日,強生視力宣佈在佛羅裡達州傑克遜維爾的強生研究所開設外科視力體驗中心。外科中心作為其首要的體育訓練空間和實驗室環境,提供各種體驗式教育計劃,為執業眼科醫生、眼科住院醫師和驗光師提供動手、深入的培訓。

收購

2021 年 7 月 14 日,拓普康公司宣布已收購眼科設備製造商 VISIA Imaging S.r.l.。此次收購將加強拓普康在眼前節設備和軟件方面的開發和製造能力。分段設備包括相機和光學相干斷層掃描 (OCT)。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按設備類型劃分的市場細分
  • 按移植類型劃分的市場細分
  • 按程序劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 視力障礙患病率上升
      • 技術進步
    • 限制
      • 使用角膜手術器械引起的不良事件
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按設備類型

    • 診斷設備
      • 眼底相機
      • 角膜曲率計
      • 角膜地形圖師
      • 眼科超聲診斷成像系統
      • 其他
    • 角膜手術設備
    • 視力保健

第 8 章按移植類型

    • 前板層角膜深層移植
    • 通孔角膜移植
    • 人工角膜
      • 波士頓人工角膜
      • alpha 調用
      • Osteo Odonto 人工角膜
    • 其他

第 9 章技術

  • 術前檢查
  • 通孔角膜移植
  • 板層角膜移植術

第 10 章,最終用戶

  • 眼科診所
  • 醫院
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • 尼迪克有限公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Johnson & Johnson
  • Essilor International S.A.
  • Topcon Corporation
  • Ziemer Ophthalmic Systems AG
  • Haag-Streit
  • Carl Zeiss Meditec
  • Bausch & Lomb
  • Abbott Medical
  • KeraMED
  • Alcon Laboratories
  • Meditec AG
  • Medical Optics Inc.
  • Cooper Vision(LIST NOT EXHAUSTIVE)

第14章 DataM

簡介目錄
Product Code: DMMD2792

Market Overview

Corneal Surgery Market was valued at USD 415.5 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.20% during the forecast period (2022-2029).

Corneal surgery is the procedure for the transplantation of the cornea for replacing the part of the cornea with corneal tissue from a donor. It involves the replacement of the diseased or scarred corneal tissue with healthy tissue from an organ donor. Corneal surgery is useful to restore vision, reduce pain and improve the appearance of a damaged or diseased cornea. Several factors such as infections including fungal keratitis, trichiasis, Fuchs' dystrophy, and keratoconus, eye injury, cornea burns, and other factors can damage the Cornea.

Corneal surgery is effective to relieve signs and symptoms associated with cornea diseases. Corneal surgery can treat various conditions such as keratoconus, Fuchs' dystrophy, cornea thinning, cornea scarring, cornea clouding, cornea swelling, corneal ulcers, and others.

Market Dynamics

Rising Prevalence of Visual Impairment is Driving the Growth of the Market

The demand for corneal surgery is increasing with the increasing number of people affected by vision impairment. According to the World Health Organization (WHO), approximately 217 million people have moderate to severe vision impairment worldwide. Around 37 million people are blind. Globally, 82% of people in the age-group 50 years and above are blind. According to Surgical Eye Expeditions International, Cornea is the leading cause of blindness globally. Around 5.1% of the global population, i.e., 12 million people, are blind due to cornea. The cornea is the major cause of visual deficiency after cataracts, glaucoma, and age-related macular degeneration. Every year, more than 350,000 children are born with or develop infections at a young age that cause corneal blindness across the globe.

Increasing funding & investment for the development of corneal surgery devices is expected to boost the market growth over the forecast period

Several organizations, associations, and foundations are raising the investment and funding for the development of corneal surgery devices. For instance, in August 2020, The Centre for Eye Research Australia's corneal researchers and the University of Melbourne received a grant of USD 500,000 from the Victorian Medical Research Acceleration Fund (VMRAF) to accelerate the development of a surgical device known as 'Corel,' an ultra-thin hydrogel film that is inserted into the donor corneal tissue into a patient's eye to restore vision. This funding would be used to support the 18 months of preclinical work to refine and test CorGel in collaboration with the University and US eye bank EverSight.

Adverse events associated with corneal surgery are hampering the Market Growth

Several adverse events associated with corneal surgery are hindering market growth. Adverse events such as infection, bleeding, pain, redness, sensitivity to light, higher pressure in the eye, and others. Corneal surgery increases the risk of developing an eye infection, clouding of the eye's lens, rejection of the donor cornea, and cornea swelling. In corneal transplants, the body's immune system attacks the donated tissue in one out of every 10 transplants. Cornea rejection can occur in 20% of the cases. Graft failure can also occur among the patients transplanted with the cornea.

COVID-19 Impact Analysis

The global corneal surgery market has been impacted due to the COVID-19 pandemic, as there has been a reduction in the number of patients undergoing corneal surgery with the increasing number of people suffering from COVID-19. COVID-19 can be a serious threat to carrying out corneal surgery. The COVID-19 pandemic has resulted from the imbalance between the supply-demand between the number of voluntary donors and corneal surgery. There is a decrease in the number of people undergoing corneal surgery as several ophthalmologists have ceased providing any treatment other than urgent or emergent care. Moreover, eye hospitals and eye banks are prohibited from taking home retrieval of eyes from dead individuals in various countries owing to the emergence of the COVID-19 pandemic. According to the Karnataka Ophthalmic Society, the number of corneal transplants has decreased by more than 90% as either people are not coming forward to donate the eyes of the dead people or there is no Covid-negative test report. Several patients have been waiting to undergo corneal surgery as there are shortages of corneas for performing the surgery. According to Parekh, Mohit et al. 2020, published in the European Journal of Ophthalmology, around 2.7 million patients are waiting for corneal transplants worldwide. Veneto Eye Bank has witnessed a 95% reduction in donor corneas from its network of 250 local and international surgeons.

Epidemiology

Corneal eye diseases are the major cause of blindness worldwide. Corneal eye diseases affect more than 10 million people worldwide. Several conditions, such as corneal opacity, trachoma, corneal scarring, corneal dystrophies, and corneal vascularization, are the leading cause of corneal blindness across the globe. According to the World Health Organization, around 146 million people are suffering from trachoma. Around 10 million are affected by trichiasis and need surgery to prevent corneal blindness. Approximately 4.9 million are blind due to trachomatous corneal scarring.

According to the Global Vision Database, corneal opacity affects around 3*21% of the population across the globe. Corneal opacity affects 4*26% of the population in East Asia, 3.58% of the population in Central Asia, 2.43% of the population in South Asia, 3.63% of the population in Central Europe, 3.43% of the population in Eastern Europe, and 2.43% of the population in Western Europe. The overall prevalence of corneal dystrophies was 897 per 1000,000 in the United States. Around 60% of all corneal dystrophies are endothelial.

Market Segment Analysis

The Deep Anterior Lamellar Keratoplasty segment is expected to hold a significant share in the Corneal Surgery market

By transplantation type, the corneal surgery market is segmented as deep anterior lamellar keratoplasty, penetrating keratoplasty, and synthetic corneas. The deep anterior lamellar keratoplasty segment is anticipated to hold the largest share in the corneal surgery treatment market owing to the increasing adoption of the deep anterior lamellar keratoplasty for the treatment of keratoconus, corneal ectasia, corneal stromal dystrophies, and corneal scars. Deep anterior lamellar keratoplasty is the surgical procedure for removing the corneal stroma down to Descemet's membrane. It is a partial-thickness cornea transplant procedure that includes the elective transplantation of the corneal stroma and leaves the native Descemet membrane and endothelium in place. It is an effective treatment for any pathology of the anterior cornea including the epithelium, Bowman's layer and stroma. The use of the deep anterior lamellar keratoplasty has demonstrated the reduced rejection rate as this surgical procedure preserves the host endothelium among the patients. The shorter healing time fewer postoperative complications and shorter use of topical steroid treatment was observed among the patients who had undergone deep anterior lamellar keratoplasty.

By Procedure Type, penetrating keratoplasty is Expected to Witness a Significant Growth Over the Forecast Period

The market is classified based on the procedure type as the pre-operative examination, penetrating keratoplasty, and lamellar keratoplasty. Penetrating keratoplasty segment accounts for a significant market share as it is the most common procedure being performed across the globe. According to the Cincinnati Eye Institute (CEI), every year, approximately 45,000 number of penetrating keratoplasty procedures are performed in the United States. Penetrating keratoplasty involves the surgical removal of the central two-thirds of the damaged cornea and insertion of a matching portion of clear, healthy donor tissue. Penetrating keratoplasty is used for the treatment, and management of corneal edema, corneal ulceration, corneal dystrophy, Fuch's dystrophy, keratoconus, and other conditions. Studies have shown that the penetrating keratoplasty grafts can survive 10 years or longer among the patients.

Geographical Analysis

North America region holds the largest market share global Corneal Surgery Market

North America region is dominating the global corneal surgery market accounted for the largest market share in 2021. The United States is expected to hold the largest share in this region owing to the increasing number of people undergoing corneal surgery with the increase in the number of people affected by visual impairment. According to the Centers for Disease Control and Prevention (CDC), around 12 million people have vision impairment including 1 million people were blind in the United States. According to the American Academy of Ophthalmology, approximately 48,229 corneal transplants were in the United States in 2013. More than one million men, women, & children of age-group nine days to 100+ years have restored their vision through corneal surgery in the United States since 1961.

There is an increase in the number of market players developing corneal surgery devices. Several companies are raising the investment & funding for the development of corneal surgery devices. There is growing usage of advanced methods for performing corneal surgery. There are several organizations, associations, and foundations that are raising awareness regarding corneal surgery. For instance, the Cornea Research Foundation of America (CRFA), a non-profit organization is involved in conducting clinical research and education specializing in corneal disease, corneal transplantation and intraocular lens surgery. Moreover, several companies are also launching their surgical vision centres. For instance, in July 2019, Johnson & Johnson had launched the Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, Florida. This centre would serve as Johnson & Johnson Vision's premier physical training space and laboratory setting for a variety of experiential educational programs offering hands-on, in-depth training for practising ophthalmic surgeons, ophthalmology residents and optometrists. The availability of better healthcare facilities and infrastructure shall stimulate market growth.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global corneal surgery market owing to the increasing prevalence of various chronic diseases such as diabetes, diabetic retinopathy, obesity, and others increase the chances of eye disorders that could lead to corneal blindness. According to the Global Alliance of Eye Bank Association (GAEBA), around 2.8 million people are affected by corneal blindness in Asia. Approximately 6.8 million people have a vision of less than 6/60 in at least one eye due to corneal diseases. Among these people, one million people have bilateral involvement. As per the National Programme for Control of Blindness (NPCB), there were 120,000 corneal blind persons in India in 2013. Every year, there is an addition of 25,000-30,000 new cases of Corneal blindness. Moreover, the National Programme for Control of Blindness and Visual Impairment was launched in India in 1976 as a 100% centrally sponsored scheme to reduce the prevalence of blindness to 0.3% by 2020. The 2016-17 program collected donated eyes for corneal transplantation and achieved 65,135 out of the target of 50,000.

The drastic market growth is expected to observe in the countries such as India, China, Japan, and Australia due to the increase in the number of ophthalmic clinics, hospitals, and other healthcare organizations providing corneal surgery. There is growing awareness regarding the importance of eye donation shall have a positive impact on the market. Several companies are focussing on developing technologically advanced corneal surgery devices. There is growing initiatives by the government for providing low-cost ophthalmic procedures in clinics and hospitals. The improvement in eye care facilities, eye banking framework and cornea trade protocols shall boost the demand for corneal surgery.

Competitive Landscape:

The corneal surgery market studied is a fragmented market with the presence of a large number of market players. Nidek Co. Ltd, Johnson & Johnson, Essilor International S.A., Topcon Corporation, Ziemer Ophthalmic Systems AG, Carl Zeiss Meditec, Bausch & Lomb, Abbott Medical, Alcon Laboratories, Meditec AG, Medical Optics Inc., and Cooper Vision are the major players with significant market share. The major players are adopting several growth strategies, such as product launches, product approvals, mergers, licensing, acquisitions, and collaborations, contributing to the growth of the global corneal surgery market. For instance,

Mergers & Collaborations:

In October 2019, TECLens entered into a collaboration with SERVimed Industrial Spa for the development and FDA approval of a new combination product to treat keratoconus. The new product under development would combine TECLens' CXLens 'on-eye' cross-linking system for corneal remodeling with SERVImed's trans-epithelial RIBOCROSS riboflavin drug formulation.

On 18th July 2022, Carl Zeiss Meditec partnered with Precise Bio to develop and commercialize fabricated corneal tissue for Ophthalmology. Under the agreement, Carl Zeiss Meditec will invest in Precise Bio to develop cornea transplant products.

Product Launch & Approvals:

On 24th May 2021, Haag-Streit UK launched the Eyestar 900 eye analyzer in the UK. The swept-source technology enables precise measurement of the entire eye and topographic assessment of the front and back corneal surface and the anterior chamber, including the lens. In addition to imaging all of these structures, it includes cornea-to-retina biometry of the entire eye.

On 31st July 2019, Johnson & Johnson Vision announced its launch of the Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, FL. The Surgical Center will serve as its premier physical training space and laboratory setting for various experiential educational programs offering hands-on, in-depth training for practicing ophthalmic surgeons, ophthalmology residents and optometrists.

Acquisition:

On 14th July 2021, Topcon Corporation announced it had acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer. This acquisition enhances Topcon development and boosts the manufacturing capacity of anterior segment devices and software. The segment devices include cameras and optical coherence tomography (OCT).

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Device Type
  • 3.2. Market Snippet by Transplantation Type
  • 3.3. Market Snippet by Procedures
  • 3.4. Market Snippet by End-User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Vision Impairment
      • 4.1.1.2. Technological Advancements
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Adverse Events with use of Corneal Surgery Devices
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type Segment
  • 7.3. Market Attractiveness Index, By Device Type Segment
    • 7.3.1. Diagnostic Devices*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.3. Fundus Cameras
      • 7.3.1.4. Keratometers
      • 7.3.1.5. Corneal Topographer
      • 7.3.1.6. Ophthalmic Ultrasound Imaging Systems
      • 7.3.1.7. Others
    • 7.3.2. Corneal Surgery Devices
    • 7.3.3. Vision Care

8. By Transplantation Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 8.3. Market Attractiveness Index, By Transplantation Type Segment
    • 8.3.1. Deep Anterior Lamellar Keratoplasty*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Penetrating Keratoplasty
    • 8.3.3. Synthetic Corneas
      • 8.3.3.1. Boston Keratoprosthesis
      • 8.3.3.2. Alphacor
      • 8.3.3.3. Osteo-Odonto-Keratoprosthesis
    • 8.3.4. Others

9. By Procedures

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 9.3. Market Attractiveness Index, By Procedures Segment
    • 9.3.1. Pre-Operative Examination*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Penetrating Keratoplasty
    • 9.3.3. Lamellar Keratoplasty

10. By End-User

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.3. Market Attractiveness Index, By End-User Segment
    • 10.3.1. Ophthalmic Clinics*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Hospitals
    • 10.3.3. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Nidek Co. Ltd*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Johnson & Johnson
  • 13.3. Essilor International S.A.
  • 13.4. Topcon Corporation
  • 13.5. Ziemer Ophthalmic Systems AG
  • 13.6. Haag-Streit
  • 13.7. Carl Zeiss Meditec
  • 13.8. Bausch & Lomb
  • 13.9. Abbott Medical
  • 13.10. KeraMED
  • 13.11. Alcon Laboratories
  • 13.12. Meditec AG
  • 13.13. Medical Optics Inc.
  • 13.14. Cooper Vision(LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us